Wataru Rikihisa

Encapsulated fat necrosis – A clinicopathological study of 8 cases and a literature review

Eight cases of encapsulated fat necrosis are described. The patients were two males and six females from 10 to 77 years of age. The majority of the lesions clinically presented as asymptomatic, multiple, mobile, small nodules. All patients were treated by simple excisions of the nodules. Grossly, the lesions were whitish‐yellow in color, smoothly‐surfaced, round nodules measuring 3 to 20 mm in the greatest diameter. Histopathologically, the nodules were basically composed of variably degenerated and necrotic fatty tissue covered by fibrous connective tissue capsule associated with occasional calcification and inflammatory cell infiltrates. Among several terms proposed for this disease, encapsulated fat necrosis is considered most preferable term based on the clinical and histological findings of the present and reported cases.

Increase in the peripheral lymphocyte populations expressing CD54 (ICAM-1) after hyperthermic isolated limb perfusion in patients with malignant melanoma: an analysis of four cases

The lymphocytes isolated from perfused or non-perfused circulations before, during, and after hyperthermic isolated limb perfusion (HILP) in the four patients with malignant melanoma were analysed for the expression of CD54 (ICAM-1), CD58 (LFA-3), CD4, CD8, HLA class I and class II in order to investigate the mechanism(s) of the activation of such immunocompetent cells as natural killer (NK)-cells or T-lymphocytes by HILP. It was thus found that the lymphocyte populations expressing CD54 increased significantly 1 day after HILP in the four patients examined. The lymphocyte populations expressing CD58 apparently increased. It was also found that the NK-cell and T-lymphocyte activities increased during or after HILP in the present four cases as observed previously in the other melanoma patients. These results indicate that our HILP system may augment the immunological activities through the mechanisms of the induction of CD54 or CD58 expression in the peripheral lymphocytes of the melanoma patients who receive HILP.